info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Nanobody Companies

Nanobody companies are at the forefront of a revolutionary field in biotechnology, specializing in the development and utilization of nanobodies. Nanobodies are unique single-domain antibody fragments derived from camelids, such as camels and llamas, and hold immense promise in various biomedical applications.

Nanobody Key CompaniesLatest Nanobody Companies Update

Nov 2023: A collaboration between Huma Therapeutics & Merck KGaA intends to inform and assist cancer patients in managing their course of therapy. Through the partnership, a Cross-Indication Disease Management Platform will be created using Huma's technology, providing patients receiving cancer treatments from Merck KGaA, Darmstadt, Germany, with access to a care pathway and educational resources. Launched in the UK in 2024, the Cross-Indication Disease Management Platform will assist patients suffering from urothelial carcinoma, a cancer that arises from urothelial cells lining the bladder, ureters, renal pelvis, and other organs. With US Food and Drug Administration (FDA) Class II 510(k) clearance and EU MDR Class IIb regulation, Huma will leverage its disease-agnostic Software as a Medical Device (SaMD) technology platform to enable the service.


The monoclonal antibody Dupixent from Sanofi and Regeneron has achieved success in a second phase 3 study for chronic obstructive pulmonary disease (COPD), making it the first biologic to treat the lung illness and the initial breakthrough in the indication in over ten years. Dupixent will have access to yet another huge market if COPD is approved. Dupixent is already on a juggernaut trajectory as a treatment for asthma, atopic dermatitis, and several other inflammatory disorders. The drug brought in $3.1 billion in the third quarter, a 33% rise year over year. The drug's revenues for the first nine months were $8.4 billion after the third quarter's success.


List of Nanobody Key companies in the market

  • Sanofi (France)

  • Merck KGaA (Germany)

  • BIOCYTOGEN (US)

  • Proteintech Group, Inc (US)

  • Novartis AG (Switzerland)

  • GenScript (US)

  • Sensei Biotherapeutics, Inc (US)

  • Beroni Group (Australia)

  • ExeVir Bio (Belgium)

  • Taisho Pharmaceutical Holdings Co., Ltd (Japan)

  • DiosCURE Therapeutics SE (Germany)

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.